Sei Naito

17PUBLICATIONS
43CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsExercise physiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Mar 17, 2026
A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.

Shuzo Hamamoto, Masahiro Nozawa, Suguru Shirotake

|Nov 26, 2025
A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS).

Masaomi Ikeda, Kiyohide Fujimoto, Noriyoshi Miura

|Nov 26, 2025
Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study.

Tomokazu Sazuka, Katsunori Tatsugami, Suguru Shirotake

|May 14, 2025
Ankrd1 Promotes Lamellipodia Formation and Cell Motility via Interaction with Talin-1 in Clear Cell Renal Cell Carcinoma.

Yuki Takai, Sei Naito, Hiromi Ito

|May 07, 2025
Association Between Overactive Bladder and Sarcopenia in Older Adults: A Population-Based Cohort Study.

Suguru Ito, Mayu Yagi, Kaori Sakurada

|Apr 24, 2025
The Effectiveness and Safety Profile of Nivolumab-Plus-Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J-ENCORE Study).

Koshiro Nishimoto, Go Kimura, Tomokazu Sazuka

Pageof 3

Frequent Collaborators

8 joint publications

Norihiko Tsuchiya

4 joint publications

Tomokazu Sazuka

4 joint publications

Takashige Abe

3 joint publications

Hironobu Asao